NPPA Approves 15% Price Increase for Ciprofloxacin Injection by Aculife Healthcare
The National Pharmaceutical Pricing Authority (NPPA) has approved a 15% increase in the ceiling price of Ciprofloxacin Injection 200mg/100ml for M/s Aculife Healthcare Pvt. Ltd., due to the special features of their packaging. The ceiling price has been fixed as Rs. 0.23/ ml (plus applicable Goods and Services Tax). Prices for all such formulations must be revised downward if they exceed the set ceiling price plus local taxes.
NPPA Revises Retail Prices for 54 New Drug Formulations
The retail price for these specified formulations must match the specified price. Manufacturers are required to submit a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and provide copies to State Drug Controllers and dealers. Retailers and dealers must clearly display the price list provided by manufacturers to ensure it is easily accessible to customers.
NPPA Revises Ceiling Price Of Budesonide (A) +Formoterol (B)
Now, by the present corrigendum NPPA has revised the ceiling price for Budesonide (A) +Formoterol (B). The ceiling price has now been fixed as Rs. 6.95/ per dose. This applies to the dosage in the form of Inhalation (DPI) 400mcg(A) +6 mcg (B).
NPPA Fixes Ceiling Price of New Drugs and Scheduled Formulations
The National Pharmaceutical Pricing Authority (NPPA) has set maximum prices for certain new drug formulations made by specific companies. Additionally, NPPA has also fixed ceiling prices for certain scheduled formulations. The ceiling prices specified are exclusive of GST and apply to the respective dosage forms, strengths, and units detailed in the entries.
Revision In Ceiling Prices Of Coronary Stents
The new ceiling prices are Rs. 10,509.79 per unit for Bare Metal Stents and Rs. 38,267.18 per unit for Drug Eluting Stents (DES). These prices are exclusive of Goods and Services Tax (GST). Manufacturers can revise their existing MRP (Maximum Retail Price) based on the new ceiling price and WPI increase.
NPPA Fixes Ceiling Price of Several Formulations under Drugs (Prices Control) Order, 2013
The manufacturer shall issue a price list in Form–V from date of Notification to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
NPPA sets Retail Prices for 19 Formulations
Manufacturers of specific formulations categorized as “new drugs” under the Drug Price Control Order (DPCO), 2013 (DPCO, 2013) are required to set the retail price as indicated in this notification. Manufacturers can add Goods and Services Tax to the retail price only if they have already paid or are liable to pay the government on the mentioned retail price. Manufacturers must issue a price list in Form–V via IPDMS to the National Pharmaceutical Pricing Authority (NPPA) and submit copies to State Drug Controllers and dealers.
NPPA Takes Measures to Ensure Price Transparency in Pharmaceutical Market
As per existing regulations, every manufacturer producing a scheduled or non-scheduled formulation for sale must prominently display the maximum retail price (MRP) on the label of the container, along with the words “Maximum Retail Price” and “inclusive of all taxes.” Additionally, manufacturers are required to issue a price list to dealers, who must prominently display it on their business premises.
NPPA sets Retail Prices for 51 Formulations
The ceiling price for a pack of scheduled formulations should be determined by the concerned manufacturer in accordance with the ceiling price specified. Manufacturers are required to issue a price list in Form-V from the date of notification, as per the Drugs Price Control Order (DPCO), 2013, to the NPPA through IPDMS. A copy of the price list should also be submitted to the State Drug Controller and dealers.
